Medicenna Therapeutics Corp.

MDNA on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
2.14CAN 0.14/7.00%4001.42 / 3.3052.10 M
MDNAF on OTCQXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
1.69US 0.00/0.00%01.29 / 1.9941.20 M

Contact Information

Medicenna Therapeutics Corp.

Headquarters:
1920 Yonge Street , Suite 200
Toronto, Ontario
Canada, M4S 3E2
Tel: (416) 648-5555
Fax: (416) 572-7501
Email: Send a message
Website: Visit website
For more information...
Lead: Laura Welsh
Media: Kellie Coppin

Medicenna  is  a  clinical  stage  immuno-oncology  company  developing  novel  highly  selective  versions  of  IL-2,  IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Its wholly owned subsidiary, Houston-based Medicenna  BioPharma,  is  specifically  targeting  the  Interleukin-4  Receptor  (IL4R),  which  is  over-expressed  by  at  least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy  and  obtained  Fast-Track  and  Orphan  Drug  status  from  USFDA.  Unlike  most  other  cancer  therapies,  Medicenna’s   IL4-ECs   have   the   potential   to   purge   both   the   tumor   and   the   immunosuppressive   tumor   microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

Fahar Merchant, PhD. - President and CEO

Elizabeth Williams, CPA, CA - Chief Financial Officer

Martin Bexon, MD - Head of Clinical Development

Rosemina Merchant, MESc - Chief Development Officer

Patrick Ward, MBA, RPh - Chief Operating Officer

Shafique Fidai, PhD. - Head of Discovery and Corporate Development

Fahar Merchant, PhD. - Chairman

Albert Beraldo, CPA, CA - Director

Rosemina Merchant, MESc - Director

Dr. Chandra Panchal, PhD. - Director

Andrew Strong, JD - Director

Dr. William Li - Director

Stock Information

Events

Nov 2, 2017 - 12:00 PM EDT Corporate Presentation - New York

Company Overview

Medicenna  is  a  clinical  stage  immuno-oncology  company  developing  novel  highly  selective  versions  of  IL-2,  IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Its wholly owned subsidiary, Houston-based Medicenna  BioPharma,  is  specifically  targeting  the  Interleukin-4  Receptor  (IL4R),  which  is  over-expressed  by  at  least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy  and  obtained  Fast-Track  and  Orphan  Drug  status  from  USFDA.  Unlike  most  other  cancer  therapies,  Medicenna’s   IL4-ECs   have   the   potential   to   purge   both   the   tumor   and   the   immunosuppressive   tumor   microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

Management

Fahar Merchant, PhD. - President and CEO

Elizabeth Williams, CPA, CA - Chief Financial Officer

Martin Bexon, MD - Head of Clinical Development

Rosemina Merchant, MESc - Chief Development Officer

Patrick Ward, MBA, RPh - Chief Operating Officer

Shafique Fidai, PhD. - Head of Discovery and Corporate Development

Board of Directors

Fahar Merchant, PhD. - Chairman

Albert Beraldo, CPA, CA - Director

Rosemina Merchant, MESc - Director

Dr. Chandra Panchal, PhD. - Director

Andrew Strong, JD - Director

Dr. William Li - Director

Contact Information

Headquarters:
1920 Yonge Street , Suite 200
Toronto, Ontario
M4S 3E2, Canada
Telephone: (416) 648-5555
Fax: (416) 572-7501
Email: Send a message
Website: Visit website